Free tool
FAERS Monitor: Afrezza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022472 or its brand name (Afrezza, Insulin Recombinant Human). Reports on generic versions are filed under their own applications.
Reports
8,026
Serious
5,651
70% of reports
Hospitalization
3,162
Death reported
789
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,327
- drug ineffective583
- hypoglycaemia458
- cough446
- blood glucose decreased398
- dyspnoea398
- hyperglycaemia357
- diarrhoea341
- off label use319
- headache283
- nausea271
- wrong technique in product usage process263
- weight decreased257
- fall250
- fatigue249
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 54 |
| 2006 | 44 |
| 2007 | 73 |
| 2008 | 69 |
| 2009 | 67 |
| 2010 | 76 |
| 2011 | 100 |
| 2012 | 96 |
| 2013 | 160 |
| 2014 | 369 |
| 2015 | 1,116 |
| 2016 | 315 |
| 2017 | 201 |
| 2018 | 512 |
| 2019 | 448 |
| 2020 | 400 |
| 2021 | 581 |
| 2022 | 791 |
| 2023 | 701 |
| 2024 | 681 |
| 2025 | 647 |
| 2026 | 471 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 357 | 25.9 | 23.4 | 8,459 |
| hypoglycaemiaSignal | 458 | 25.0 | 22.8 | 10,440 |
| blood glucose decreasedSignal | 398 | 21.9 | 19.9 | 7,867 |
| blood glucose increasedSignal | 1,327 | 18.6 | 17.7 | 22,100 |
| coughSignal | 446 | 4.2 | 3.8 | 1,086 |
| wrong technique in product usage processSignal | 263 | 3.4 | 3.0 | 448 |
| weight decreasedSignal | 257 | 2.4 | 2.1 | 214 |
| fall | 250 | 2.0 | 1.7 | 120 |
| dyspnoea | 398 | 1.8 | 1.7 | 157 |
| diarrhoea | 341 | 1.4 | 1.2 | 37 |
| headache | 283 | 1.2 | 1.1 | 8 |
| drug ineffective | 583 | 1.2 | 1.1 | 13 |
| off label use | 319 | 1.0 | 0.9 | 1 |
| nausea | 271 | 0.9 | 0.8 | 3 |
| fatigue | 249 | 0.8 | 0.7 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.